These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

502 related items for PubMed ID: 18839649

  • 21. [Pathophysiological background for incretin therapy: is it capable of more than we think?].
    Haluzík M, Urbanová M, Haluzíková D, Trachta P.
    Vnitr Lek; 2011 Nov; 57(11):897-902. PubMed ID: 22165692
    [Abstract] [Full Text] [Related]

  • 22. The physiologic role of incretin hormones: clinical applications.
    Cefalu WT.
    J Am Osteopath Assoc; 2010 Mar; 110(3 Suppl 2):S8-S14. PubMed ID: 20382839
    [Abstract] [Full Text] [Related]

  • 23. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
    Nauck MA.
    Horm Metab Res; 2004 Mar; 36(11-12):852-8. PubMed ID: 15655719
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.
    Neumiller JJ.
    Clin Ther; 2011 May; 33(5):528-76. PubMed ID: 21665041
    [Abstract] [Full Text] [Related]

  • 28. Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight.
    Bonora E.
    Int J Clin Pract Suppl; 2007 Aug; (154):19-28. PubMed ID: 17593274
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Dipeptidyl peptidase-IV inhibitors can restore glucose homeostasis in type 2 diabetics via incretin enhancement.
    Mest HJ.
    Curr Opin Investig Drugs; 2006 Apr; 7(4):338-43. PubMed ID: 16625820
    [Abstract] [Full Text] [Related]

  • 33. The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus.
    Zarowitz BJ, Conner C.
    Pharmacotherapy; 2009 Dec; 29(12 Pt 2):55S-67S. PubMed ID: 19947817
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Potential cardiovascular effects of incretin-based therapies.
    Deacon CF, Marx N.
    Expert Rev Cardiovasc Ther; 2012 Mar; 10(3):337-51. PubMed ID: 22390806
    [Abstract] [Full Text] [Related]

  • 37. [Antidiabetics and the incretin system].
    Høibraaten E, Folkersen J.
    Tidsskr Nor Laegeforen; 2008 Sep 11; 128(17):1985. PubMed ID: 18787580
    [No Abstract] [Full Text] [Related]

  • 38. Gliptins: a new class of oral hypoglycaemic agent.
    Chahal H, Chowdhury TA.
    QJM; 2007 Nov 11; 100(11):671-7. PubMed ID: 17881415
    [Abstract] [Full Text] [Related]

  • 39. Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes.
    Pratley RE.
    J Am Acad Nurse Pract; 2008 Nov 11; 20 Suppl 1():7-11. PubMed ID: 19402254
    [No Abstract] [Full Text] [Related]

  • 40. Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapies.
    Fonseca VA, Zinman B, Nauck MA, Goldfine AB, Plutzky J.
    Am J Med; 2010 Jul 11; 123(7):S2-S10. PubMed ID: 20609666
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.